Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Medical World News

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

COPD

COVID-19

Cholangiocarcinoma

Chronic Kidney Disease

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Digital Health

Employers

Epilepsy

Heart Failure

Hematology

Hemophilia

Immuno-Oncology

Infectious Disease

Inflammation

Leukemia and Lymphoma

Liver

Lung Cancer

Lupus

Major Depressive Disorder

Medicare

Multiple Myeloma

Myasthenia Gravis

Myelodysplastic Syndromes

Oncology

Ophthalmology

Ovarian Cancer

Parkinson Disease

Prostate Cancer

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Rare Disease

Reimbursement

Respiratory

Rheumatology

Skin Cancer

Sleep

Spinal Muscular Atrophy

Type 1 Diabetes

Vaccines

Women's Health

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

eNewsletter

Videos

Jason Westin, MD, MS, FACP, director of the Lymphoma Clinical Research Program at the University of Texas MD Anderson Cancer Center, gave insight the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in relapsed or refractory large B-cell lymphoma (R/R LBCL) and the study's implications in the broader LBCL landscape. 

ZUMA-7 Findings Show Earlier Is Better for Axi-Cel Use in R/R LBCL, Says Dr Jason Westin

Articles

In this interview, Tycel Phillips, MD, associate professor of medicine, Division of Lymphoma and Bone Marrow Transplantation, City of Hope, Duarte, California, discusses the advancements that are shaping the future of B-cell lymphoma treatment, as well as access barriers.




Dr Tycel Phillips on Progress in B-cell Lymphoma Treatment

, Robin Gelburd, JD, built the organization into a trusted national leader in health care cost transparency, data analytics and benchmarks, utilizing its vast collection of 34 billion private health care claim records that grows at a rate of over 2 billion claim records a year—the largest such repository in the country. Certified by CMS as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D. Robin is a nationally recognized expert and conference speaker on health care policy and health literacy and transparency. She has overseen FAIR Health research publications on many health care topics, including COVID-19, the opioid crisis and Lyme disease, and created and supervises FAIR Health’s Monthly Telehealth Regional Tracker, an online resource on telehealth.

In March 2023, national telehealth utilization rose 1.8%, up from 5.5% of medical claim lines in February, according to new data from FAIR Health’s Monthly Telehealth Regional Tracker.

Contributor: Mental Health Conditions Rose Nationally in Share of Telehealth Claim Lines

Mary is the associate editorial director for The American Journal of Managed Care® (AJMC®), The Center for Biosimilars®, and Evidence-Based Oncology™. She joined AJMC® in 2013 and oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®.

She has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on 

In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need.

Trastuzumab Deruxtecan Brings Encouraging Responses in HER2-Expressing Cancers Across Multiple Tumor Types

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Stakeholders

Academia

Health System

Payers

Providers

Topics

Institute for Value-Based Medicine

All Coverage

Event Coverage

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

View

Participating Faculty

Selected Abstracts

Bibliography

The Role of the ECHO Model in Outcomes Research and Clinical Practice Improvement

Economic Outcomes of a Targeted Intervention Program:  The Costs of Treating Allergic Rhinitis Patients

Effect of Fexofenadine HC1 on Quality of Life and Work, Classroom, and Daily Activity Impairment in Patients with Seasonal Allergic Rhinitis

Diagnosis and Treatment of Allergic Rhinitis:  Primary Care in an Integrated Health System Setting

CME Quiz

A Multidisciplined Approach to Improving the Treatment of Allergic Rhinitis in the Managed Care Popu

SUPPLEMENT CONTENT

Supplements

Publications